Endocrine-disrupting chemicals: economic, regulatory, and policy implications - Archive ouverte HAL Access content directly
Journal Articles The Lancet. Diabetes & Endocrinology Year : 2020

Endocrine-disrupting chemicals: economic, regulatory, and policy implications

(1) , (2) , (3) , (4, 5, 6, 7) , (8, 9) , (10, 11)
1
2
3
4
5
6
7
8
9
10
11

Abstract

Endocrine-disrupting chemicals (EDCs) substantially cost society as a result of increases in disease and disability but—unlike other toxicant classes such as carcinogens—have yet to be codified into regulations as a hazard category. This Series paper examines economic, regulatory, and policy approaches to limit human EDC exposures and describes potential improvements. In the EU, general principles for EDCs call for minimisation of human exposure, identification as substances of very high concern, and ban on use in pesticides. In the USA, screening and testing programmes are focused on oestrogenic EDCs exclusively, and regulation is strictly risk-based. Minimisation of human exposure is unlikely without a clear overarching definition for EDCs and relevant pre-marketing test requirements. We call for a multifaceted international programme (eg, modelled on the International Agency for Research in Cancer) to address the effects of EDCs on human health—an approach that would proactively identify hazards for subsequent regulation.

Dates and versions

inserm-03176803 , version 1 (22-03-2021)

Identifiers

Cite

Christopher Kassotis, Laura Vandenberg, Barbara Demeneix, Miquel Porta, Rémy Slama, et al.. Endocrine-disrupting chemicals: economic, regulatory, and policy implications. The Lancet. Diabetes & Endocrinology , 2020, 8 (8), pp.719-730. ⟨10.1016/S2213-8587(20)30128-5⟩. ⟨inserm-03176803⟩
33 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More